Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity

Hartnett, M. Elizabeth

doi:10.1016/j.clp.2014.08.011

Cited by 55 publications

(53 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Tüm dünyada hem gelişmiş hem de gelişmekte olan ülkelerde çocukluk çağındaki önlenebilir körlüğün en önemli sebebini oluşturan PR, şimdiye kadar dünya genelinde yaklaşık 50.000 çocukta kalıcı görme kaybına neden olmuştur. 2 Gelişen teknolojik ve yenidoğan yoğun bakım üniteleri (YYBÜ) imkanları yardımıyla yaşatılabilen prematüre bebeklerin sayısı arttıkça prematüriteye bağlı komplikasyonların dolayısıyla PR'nin sıklığı da artmıştır.…”

unclassified

Incidence, Risk Factors and Treatment Outcomes of Retinopathy of Prematurity in the Southeastern Anatolian Region Province of Şanlıurfa in Turkey

Özcan¹,

Con²,

Çelik³

2015

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

(sırasıyla, p<0,001, p<0,001, p<0,001, p<0,001). S So on nu uç ç: : İlimizde, genel PR görülme sık-lığının (%30) Türkiye ortalamasıyla benzer oranlarda görülmesine rağmen agresif seyirli arka PR (%3) ve şiddetli PR (%12,6) görülme sıklığının yüksek olduğu saptandı. Sunulan sağlık hizmetleri politikasının bir parçası olarak Şanlıurfa'da, PR hastalığını görmeyi tehdit edici seviyelere ulaşma-dan önce saptayabilmek için etkili ve uygun bir tarama programı oluşturulmalıdır.A An na ah h t ta ar r K Ke e l li i m me e l le er r: : Prematüre retinopatisi; insidans; risk faktörleri A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : To determine the current incidence and risk factors of retinopathy of prematurity (ROP) and to evaluate treatment choices of ROP. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Two hundred thirty four premature infants, whose the mean birth week was 30.6±2.3 weeks, who had been screened for ROP between May 2014 and June 2015 were enrolled this retrospective study. Infants with ROP were classified according to the gestational age and birth weight. Risk factors were analyzed in infants with ROP. Infants with in need of treatment have been treated, based on the severity of ROP, via either laser photocoagulation (LP) or intravitreal (IV) anti-VEGF injection or LP combined with IV anti-VEGF injection. R Re es su ul lt ts s: : Among the 234 infants, the mean gestational age (GA), mean birth weight (BW), mean follow-up period were 30.6±2.3 weeks, 1573±430 gram and 14.5±4 weeks respectively. Overall, the incidence at any stage of ROP was 30% and severe (Type 1) ROP was 12.6%. Seven of all patients diagnosed with Type 1 ROP had aggressive posterior ROP. The incidences of ROP in babies with gestational age (GA) ≥34 weeks or birth weight (BW) ≥2000 gram were 24% and 18% respectively. Among all risk factors contributed to development of ROP low GA, low BW, septicemia and respiratory distress syndrome were significantly associated with ROP (p<0.001, p<0.001, p<0.001, p<0.001 respectively). C Co on nc cl lu us si io on n: : Although the overall incidence of ROP (30 %) seems to be similar to the average of Turkey, incidence of aggressive post ROP (3%) and severe ROP (12.6 %) is much higher. As a part of general health polices, an effective and compatible screening programs for detecting ROP before reaching sight-threatening levels should be established for Şanlıurfa.

show abstract

unclassified

Incidence, Risk Factors and Treatment Outcomes of Retinopathy of Prematurity in the Southeastern Anatolian Region Province of Şanlıurfa in Turkey

Özcan¹,

Con²,

Çelik³

2015

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

show abstract

“…Animal models of oxygen-induced retinopathy (OIR) studies have shown vascular endothelial growth factor (VEGF) to be a key player in the pathogenesis of ROP 3. This has resulted in clinicians using intravitreal anti-VEGF to treat ROP 4. In a recently published Cochrane Systematic Review titled ‘Anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinopathy of prematurity’, the authors evaluated data from three clinical trials, in which 239 premature infants were participated 5.…”

Section: Introductionmentioning

confidence: 99%

The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review

et al. 2016

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP), a vasoproliferative disorder exclusive to premature infants is an important cause of childhood blindness. The number of premature infants surviving with this condition is expected to increase globally. Animal models of oxygen-induced retinopathy studies have shown vascular endothelial growth factor (VEGF) to be a key player in the pathogenesis of ROP. This has led to increased use of VEGF antagonist as an alternative treatment for ROP. The purpose of this systematic review is to determine the association between VEGF and ROP in human newborn. The literature review identified 12 studies to date which fulfilled the search criteria. Investigators used cord blood, serum, plasma and tissue samples to investigate the association between ROP and VEGF. Studies that measured VEGF in cord blood found mixed results, with low VEGF (at birth) associated with ROP in one study and no difference noted in two others. Mixed results were also seen in studies determining VEGF in postnatal venous samples. Four studies showed no difference in VEGF level between premature infants with and without ROP, one study showed an increased VEGF level in premature infants with ROP and another study found serum VEGF to be low in premature infants with ROP. The most recent study demonstrated an initial increase in serum VEGF followed by a decline at the time of treatment. These contradictory results indicate that we are yet to fully understand the role of VEGF in human premature infants and question the rationale of treating ROP with anti-VEGF. Anti-VEGF therapy results in systemic effect on serum VEGF levels for up to 2 months and this could have an effect on neurodevelopmental outcome. The effect of this on other developing organs is currently unknown. More studies are required to determine the mechanistic relationships between systemic VEGF and ROP in premature infants.

show abstract

“…We hypothesize that factors which protect the foetus from development of severe ROP include elevated anti-angiogenic factors in maternal blood may pass through the placenta to enter foetal circulation or anti-angiogenic factors in amniotic fluid may be absorbed through cornea into retina of the foetus or there may be genetic tendency of the foetus to produce more antiangiogenic factors (sFlt1, sEng) in response to hypoxia, 8 both in the placenta (foetal tissue) and the retina.…”

Section: Future Scope Of Our Studymentioning

confidence: 99%

A Study on Association of Maternal Preeclampsia and Retinopathy of Prematurity

Senthil¹,

Thasneemsuraiya²,

Soundharya³

et al. 2016

jemds

View full text Add to dashboard Cite

BACKGROUNDWith improved neonatal care and better survival rate of premature babies, incidence of Retinopathy of Prematurity (ROP) in our country is on the increasing trend. As we know there are many foetal and maternal risk factors influencing the development of ROP, not all preterm babies develop ROP. MATERIALS AND METHODSThe aim of this study is to determine the effect of maternal pre-eclampsia on development and severity of ROP among preterm babies delivered in our Govt. Rajaji Hospital; 200 babies with birth weight less than 1750 grams and less than 34 weeks of gestation were taken up for this prospective observational study. Babies of mothers with gestational hypertension, eclampsia, chronic hypertension, preeclampsia superimposed on chronic hypertension, babies with congenital anomalies and who expired before completion of ROP screening were excluded. RESULTSAmong 140 babies of normotensive mothers and 60 babies of preeclampsia mothers, 43.6% and 45% had developed any stage of ROP respectively. Incidence of severe ROP in babies of normotensive mothers was 13.6%, whereas it was 3.3% in babies of preeclampsia mothers. Statistical analysis done using student's t-test, "P" value was found to be < 0.05. CONCLUSIONWe conclude that maternal preeclampsia is a protective factor for the development of severe ROP. KEYWORDS BACKGROUNDRetinopathy of Prematurity (ROP) is a disease characterised by abnormalities in the vascular development of retina in premature infants. With improved neonatal care and better survival rate of premature babies, incidence of ROP in our country is on the increasing trend. ROP incidence increases 1 with decreasing Gestational Age (GA) and Birth Weight (BW); however, not in all preterm babies. So, there might be other foetal and/or maternal risk factors influencing the development of ROP. These factors may protect or increase the probability of development of ROP.

show abstract

Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity

Cited by 55 publications

References 80 publications

Incidence, Risk Factors and Treatment Outcomes of Retinopathy of Prematurity in the Southeastern Anatolian Region Province of Şanlıurfa in Turkey

Incidence, Risk Factors and Treatment Outcomes of Retinopathy of Prematurity in the Southeastern Anatolian Region Province of Şanlıurfa in Turkey

The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review

A Study on Association of Maternal Preeclampsia and Retinopathy of Prematurity

Contact Info

Product

Resources

About